Drug-eluting Balloon Catheters Market Size - By Product [Coronary Artery & Peripheral Vascular Disease Catheters (Paclitaxel, Sirolimus)], Material (Polyurethane, Nylon), End-use & Global Forecast, 2023-2032

Drug-eluting Balloon Catheters Market Size - By Product [Coronary Artery & Peripheral Vascular Disease Catheters (Paclitaxel, Sirolimus)], Material (Polyurethane, Nylon), End-use & Global Forecast, 2023-2032

Drug-eluting balloon catheters market is projected to expand at 11.5% CAGR from 2023 to 2032. The rising prevalence of cardiovascular diseases across the globe is escalating the demand for effective treatment options.

The rising advancements in medical technologies and the development of innovative catheter designs is enhancing the efficacy of drug-eluting balloon procedures, attracting both patients and healthcare providers. For instance, in May 2022, Medtronic received the FDA approval for the IN. PACT 018 Paclitaxel-Coated PTA balloon catheter, a drug-coated balloon (DCB) for interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries. Additionally, the growing aging population is contributing to the increased incidences of coronary artery diseases, further fueling the demand for drug-eluting balloon catheters. Moreover, the influx of favorable reimbursement policies and the rise in government initiatives for supporting the adoption of advanced medical devices will boost the market growth.

The drug-eluting balloon catheters market is segregated into product, material, end-use, and region.

Based on product, the market value from the coronary artery disease drug eluting balloon catheters segment is projected to rise at 11.8% CAGR between 2023 to 2032. The growth can be attributed to the increasing prevalence of coronary artery diseases and the rising advancements in catheter technologies. The heightening demand for minimally invasive treatment options will also drive the segment growth.

Drug-eluting balloon catheters market share from the nylon material segment is estimated to witness 11.4% CAGR from 2023 to 2032. This is due to the favorable properties offered by nylon for catheter construction, including flexibility and durability. Moreover, the biocompatibility of nylon coupled with its ability to effectively deliver drugs during angioplasty procedures will enhance the overall performance of drug-eluting balloon catheters.

Regionally, the Asia Pacific drug eluting balloon catheter industry size is projected to expand at 14.6% CAGR from 2023 to 2032. The growth can be attributed to the growing prevalence of cardiovascular diseases, increasing awareness about minimally invasive treatment options, and the well-established healthcare infrastructure. The expanding patient pool is leading to the growing focus on improving healthcare accessibility. Additionally, the rising advancements in medical technologies and favorable government initiatives will accelerate the regional product demand.